We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Platelet RNA Tests Detects Cancer

By LabMedica International staff writers
Posted on 01 Dec 2015
Cancer is primarily diagnosed by clinical presentation, radiology, biochemical tests, and pathological analysis of tumor tissue, increasingly supported by molecular diagnostic tests.

A ribonucleic acid (RNA) test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analyzing a sample equivalent to one tiny sample of blood. More...
Using this new method for blood-based RNA tests of blood platelets, scientists have been able to identify cancer with 96% accuracy.

An international team of scientists including those at Umea University (Sweden) studied blood samples from 283 individuals of which 228 people had some form of cancer and 55 showed no evidence of cancer. To minimize effects of long-term storage of platelets at room temperature and loss of platelet RNA quality and quantity, samples were processed within 48 hours after blood collection. By comparing the blood samples RNA profiles, team could identify the presence of cancer with an accuracy of 96% among patients. Among the 39 patients in the study in which an early detection of cancer had been made, 100% of the cases could be identified and classified.

Tumor tissues of patients were analyzed for the presence of genetic alterations by tissue DNA sequencing, including next-generation sequencing SnaPShot (Thermo Fisher; Waltham MA, USA) assessing 39 genes over 152 exons with an average sequencing coverage of greater than 500. Immunohistochemistry and fluorescent in situ hybridization (FISH) were also used. In follow-up tests using the same method, the investigators could identify the origin of tumors with a so far unsurpassed accuracy of 71% in patients with diagnosed cancer in the lung, breast, pancreas, brain, liver, colon and rectum. The samples could also be sorted in subdivisions depending on molecular differences in the cancer form, which can be of great use in the choice of treatment method.

Jonas A. Nilsson, PhD, a coauthor of the study said, “Being able to detect cancer at an early stage is vital. We have studied how a whole new blood-based method of biopsy can be used to detect cancer, which in the future renders an invasive cell tissue sample unnecessary in diagnosing lung cancer, for instance. In the study, nearly all forms of cancer were identified, which proves that blood-based biopsies have an immense potential to improve early detection of cancer.” The study was published on October 29, 2015, in the journal Cancer Cell.

Related Links:

Umea University 
Thermo Fisher



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Platelet Function Analyzer
PL-12
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.